

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Posaconazole

December 17, 2021

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Posaconazole

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS</p> <p>Patients receiving ergotamine tartrate/anhydrous caffeine/ isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], or lurasidone hydrochloride</p>			<p>2. CONTRAINDICATIONS</p> <p>Patients receiving ergotamine tartrate/anhydrous caffeine/ isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozide, quinidine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], <u>suvorexant, lurasidone hydrochloride, or blonanserin</u></p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-Administration</p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-Administration</p>		
Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors	Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
(N/A)			<u>Suvorexant</u>	<u>The effects of suvorexant may be enhanced markedly.</u>	<u>The plasma concentration of suvorexant is expected to rise due to inhibition of CYP3A4 by co-administration with posaconazole.</u>
Lurasidone hydrochloride	The effects of <u>lurasidone hydrochloride</u> may	The blood concentration of <u>lurasidone</u> is expected to rise due to inhibition of CYP3A4 by	Lurasidone hydrochloride, <u>blonanserin</u>	The effects of <u>these drugs</u> may be enhanced.	The blood concentration of <u>these drugs</u> is expected to rise due to inhibition of CYP3A4 by

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

	be enhanced.	co-administration with posaconazole.			co-administration with posaconazole.
--	--------------	-----------------------------------------	--	--	-----------------------------------------

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp